Tirzepatide showed a stronger signal in patients with heart failure and type 2 diabetes
In an exploratory analysis from SURPASS-CVOT, tirzepatide produced lower rates of several cardiovascular and heart failure outcomes than dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease, including those with a history of heart failure. The comparison matters because this was not a low-risk diabetes cohort; every participant entered the trial with cardiovascular disease, and 20.3% had prior heart failure at baseline. Patients with heart failure also carried a heavier burden of coronary artery disease and previous myocardial infarction, which fits the clinical pattern seen in everyday practice: once heart failure is part of the history, vascular risk tends to cluster and intensify.
The overall study had already established non-inferiority, but the subgroup results sharpen the picture for bedside decision-making. In patients with heart failure, the hazard ratio for all-cause death or hospitalization or urgent visits for heart failure was 0.83 with tirzepatide versus dulaglutide, with a 95% confidence interval of 0.70 to 0.99. In those without heart failure, the hazard ratio was 0.88, with a 95% confidence interval of 0.78 to 1.00. The pattern was similar, though less pronounced, for the cardiovascular death or heart failure composite: 0.85 in the heart failure group and 0.96 in the no-heart-failure group. In a population already enriched for vascular risk, even modest shifts in hospitalization and death can translate into meaningful clinical separation over time.
A heavier event burden tracked with prior heart failure
Participants with a prior history of heart failure had more events across the board. Their baseline profile was more atherosclerotic, and their follow-up course reflected that burden. The analysis examined MACE-3 — cardiovascular death, myocardial infarction, and stroke — as well as MACE-4, which adds coronary revascularization to that endpoint set. Across both HF strata, event rates were higher among those with a heart failure history, a reminder that heart failure in type 2 diabetes is rarely an isolated problem; it usually marks a broader syndrome of myocardial, renal, and vascular injury.
Tirzepatide did not simply track one favorable endpoint and miss the rest. In the heart failure subgroup, the hazard ratio for MACE-3 was 0.90, with a 95% confidence interval of 0.76 to 1.08. For MACE-4, the hazard ratio was 0.81, with a 95% confidence interval of 0.69 to 0.95. Among patients without heart failure, the corresponding hazard ratios were 0.93 for MACE-3 and 0.91 for MACE-4. The most consistent separation emerged with the broader MACE-4 endpoint, especially in patients who already carried a heart failure diagnosis.
The result is clinically plausible. Tirzepatide acts through dual incretin activity, and its metabolic effects extend beyond glycemic lowering. Reduced body weight, lower blood pressure, and improved lipid parameters can each ease hemodynamic load and blunt atherothrombotic risk. In a patient with both diabetes and heart failure, those changes may matter more than glucose lowering alone, because the dominant threat is often not hyperglycemia in isolation but the combined pressure of ischemia, volume stress, and progressive myocardial dysfunction.
Quality of life improved alongside clinical outcomes
Patient-reported outcomes moved in the same direction as the event data. APPADL scores improved, and EQ-5D-5L visual analogue scores were higher with tirzepatide in both the heart failure and no-heart-failure groups. That matters because trial endpoints can look clean on paper while patients still struggle with fatigue, dyspnea, limited activity, and the practical burden of daily illness. Here, the reported improvement in functional status and overall health perception suggests the treatment effect was not confined to adjudicated events.
The quality-of-life findings also fit the biology. Weight reduction alone can make walking, climbing stairs, and routine self-care easier in people with heart failure, especially when obesity and diabetes amplify exertional symptoms. Better glycemic control may further reduce osmotic symptoms and day-to-day instability. For clinicians, patient-reported outcomes are not a secondary nicety; they often determine whether a regimen is sustainable once the trial ends and real-world adherence becomes the limiting factor.
What the subgroup analysis can and cannot claim
This remains an exploratory analysis, and the subgroup framework should be read with appropriate caution. The trial compared tirzepatide up to 15 mg weekly with dulaglutide 1.5 mg weekly over an average of about four years, but the heart failure comparison was not a dedicated heart failure outcomes trial. The data do not prove superiority for every cardiovascular endpoint, and the confidence intervals for several outcomes crossed unity. Still, the overall pattern favored tirzepatide, particularly for the composite of all-cause death or heart failure events and for MACE-4 in patients with heart failure.
For practice, the most useful interpretation is narrow and concrete: in patients with type 2 diabetes, established atherosclerotic cardiovascular disease, and a prior history of heart failure, tirzepatide showed lower rates of the combined death-and-heart-failure endpoint than dulaglutide, while also improving patient-reported outcomes. In the same population, the broader cardiovascular signal leaned in the same direction. Those findings support the idea that incretin-based therapy may carry value not only for metabolic control but also for risk modification in a particularly fragile subgroup.
The next question is not whether heart failure matters in diabetes; it clearly does. The more relevant issue is how strongly tirzepatide can be positioned relative to other incretin therapies when clinicians are trying to reduce both vascular events and the day-to-day burden of heart failure in a single patient. This analysis moves that discussion forward, but it does not replace a dedicated outcomes trial powered specifically for heart failure populations.